Nikhil Prasad Fact checked by:Thailand medical News Team Aug 07, 2024 3 months, 1 week, 5 hours, 3 minutes ago
Alzheimer News: Researchers have identified crucial biomarkers that could revolutionize the early diagnosis and treatment of Alzheimer’s disease (AD) and mild cognitive impairment (MCI). These news study findings highlight the roles of Human Leukocyte Antigen (HLA) variants and microRNAs (miRNAs) in cognitive decline. This
Alzheimer News report delves into the significance of these biomarkers and their potential impact on public health.
The Role of Human Leukocyte Antigen and microRNAs in Alzheimer’s Disease
Alzheimer's Disease and Mild Cognitive Impairment: An Overview
Alzheimer’s disease is a progressive neurodegenerative disorder characterized by memory loss, cognitive decline, and behavioral changes. It is the most common cause of dementia, affecting millions of people globally. Mild cognitive impairment (MCI) is a condition that often precedes dementia and is marked by noticeable cognitive changes that are not severe enough to interfere with daily life. However, MCI can progress to AD, making early detection and intervention crucial.
The Role of Human Leukocyte Antigen (HLA)
HLA molecules play a vital role in the immune system by presenting foreign antigens to immune cells. Variations in HLA genes can influence susceptibility to various diseases, including AD. The systematic review, conducted by researchers from the “Iuliu-Hațieganu” University of Medicine and Pharmacy in Cluj-Napoca, Romania, identified specific HLA variants associated with cognitive decline.
Key findings include:
-Predisposing HLA Variants: HLA-B4402, HLA-A33:01, HLA-DPB1, HLA-DR15, HLA-DQB103:03, HLA-DQB106:01, HLA-DQB1*03:01, and SNPs on HLA-DRB1/DQB1 have been linked to an increased risk of MCI and AD.
-Protective HLA Variants: HLA-A101, HLA-DRB113:02, HLA-DRB104:04, and HLA-DRB104:01 exhibit protective roles, potentially delaying the onset of cognitive decline.
These findings suggest that HLA genotyping could be used to identify individuals at risk for developing AD, enabling early intervention and personalized treatment strategies.
MicroRNAs: Tiny Molecules with a Big Impact
MicroRNAs (miRNAs) are small, non-coding RNAs that regulate gene expression post-transcriptionally. They are involved in various cellular processes, including inflammation, apoptosis, and cell proliferation. In the context of AD, miRNAs have emerged as promising biomarkers for early diagnosis and therapeutic targets.
The meta-analysis conducted as part of the review identified several miRNAs with significant roles in AD pathology:
-Amyloid-Beta (Aβ) Regulation: miRNAs such as miR-200, miR-137, miR-15b, miR-98, and miR-101 are involved in Aβ production and clearance.
-Tau Protein Phosphorylation
g>: miR-125, miR-138, and miR-146 influence tau phosphorylation, while miR-132, miR-369, miR-483-5p, miR-181c, and miR-212 are protective against tau aggregation.
-Neuroinflammation: miR-155, miR-34a, and miR-181a are implicated in inflammatory responses within the brain.
The dysregulation of these miRNAs in AD patients compared to healthy controls underscores their potential as diagnostic biomarkers. Moreover, miRNAs offer a non-invasive diagnostic tool since they can be detected in bodily fluids such as blood and saliva.
Diagnostic and Therapeutic Potential of HLA and miRNAs
The integration of HLA and miRNA biomarkers in clinical practice could transform the approach to diagnosing and managing MCI and AD.
The meta-analysis identified let-7 and miR-15/16 as biomarkers for the early detection of AD.
Early detection through non-invasive tests for miRNAs and HLA genotyping could enable timely interventions, potentially slowing disease progression.
For instance, saliva or blood tests that detect specific miRNA patterns could identify individuals in the early stages of cognitive decline. This early diagnosis would allow healthcare providers to implement preventive measures and personalized treatment plans tailored to the genetic and molecular profiles of patients.
Additionally, targeting miRNAs therapeutically offers a new avenue for treatment. Modulating the expression of specific miRNAs could alter disease progression, providing a novel strategy for managing AD. For example, therapies designed to increase the levels of protective miRNAs or decrease the levels of pathogenic miRNAs could mitigate the effects of AD.
Implications for Public Health
The identification of HLA variants and miRNAs as biomarkers for AD and MCI has significant implications for public health. Early diagnosis and intervention are critical for improving patient outcomes and quality of life. By identifying individuals at high risk for cognitive decline, healthcare systems can implement targeted screening programs and preventive measures.
Moreover, understanding the genetic and molecular underpinnings of AD can lead to the development of personalized medicine approaches. Patients could receive treatments tailored to their specific genetic and molecular profiles, maximizing the efficacy of interventions and minimizing adverse effects.
Conclusion
The study findings, published in the peer-reviewed journal "International Journal of Molecular Sciences," highlight the potential of HLA variants and miRNAs as biomarkers for early detection and intervention in Alzheimer’s disease and mild cognitive impairment.
https://www.mdpi.com/1422-0067/25/15/8544
These discoveries pave the way for improved diagnostic tools and therapeutic strategies, offering hope for better management of these debilitating conditions.
For the latest Alzheimer News, keep on logging to Thailand Medical News.
Read Also:
https://www.thailandmedical.news/news/new-study-reveals-link-between-high-fat-diet-and-alzheimer-s-disease
https://www.thailandmedical.news/news/herbs-and-phytochemicals-creeping-spinach-a-natural-ally-against-alzheimer-s
Share
Tweet
Share
